Latest Kaiser Health News Stories
The New York congressman was a major investor in an Australian biotechnology firm and prosecutors allege that he tipped off his son and others to sell stock shortly before the company reported poor results in its drug testing.
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
Gabapentin, a medication approved to help patients with nerve pain or epilepsy, is being abused by people addicted to opioids to help prolong their high or stave off withdrawal from other drugs. Kaiser Health News reporter Carmen Heredia Rodriguez talks about the problem during a wide-ranging health discussion on the NPR program “On Point.”
Fentanyl and other painkillers marketed as safer than Purdue Pharma’s blockbuster drug left their own trail of overdose deaths.
The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico, and Erin Mershon of Stat News discuss a series of health policy court decisions on everything from prescription drug discounts to soda taxes. Plus, Rovner, interviews health care futurist and consultant Jeff Goldsmith.
Some state Medicaid programs are not paying for the procedures, and Medicare’s complicated payment rates have hospitals concerned that it will not cover all the costs.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the health politics of the latest Supreme Court pick, as well as the Trump administration’s efforts to further undermine the Affordable Care Act. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Anna Edney of Bloomberg News discuss the latest enrollment numbers for the Affordable Care Act, Medicaid work requirements in Kentucky and President Donald Trump’s proposed government reorganization plan. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, or PrEP, because of the drug’s high price and insurance company efforts to restrict the use of coupons that shield patients from it.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
Purdue Pharma planned an extensive marketing campaign for the launch and promotion of the painkiller OxyContin. Here are Purdue’s internal budget documents from 1996 to 2002 — files released by the Florida attorney general’s office — that detail the company’s early strategy to sell and expand use of the drug.